Nurses competence in the reporting of medication-related incidents: An intervention study

Nurs Open. 2022 Nov;9(6):2836-2846. doi: 10.1002/nop2.988. Epub 2021 Jul 22.


Objectives: Less than 5% of all harmful medicine-related incidents (MIs) or adverse drug reactions received by the Spanish Pharmacovigilance system are notified by Registered Nurses (RNs). The main objective of this study was to determine the impact of a multifaceted institutional intervention (MII) in patient safety on the reporting competence of medication incidents of hospital RNs.

Design: One-group pre-test-posttest design.

Setting: Tertiary, public, teaching hospital in Spain.

Participants: A total of 139 RNs responded to pre- and postintervention questionnaires constituting the paired sample subjected to analysis.

Intervention: A MII, consisting of educational activities and materials, change in MI reporting form from paper to electronic and appointment of reporting support services, was designed and directed to all hospital RNs and midwifes.

Main outcome measures: Overall MIs reporting competence (OC) and its dimensions (attitudes, knowledge and skills) were measured through a synthetic variable (total OC value range: 34-170 points) by means of an electronic questionnaire.

Results: A statistically significant 7.96-point increase in OC from baseline to the final measurement was obtained (CI: 5.05-10.85). There was an increase of 7.38 points in the skills dimension (CI: 5.06-9.68). After the MII, 73.4% nurses improved their OC and 33.8% reported at least one no-harm MI postintervention compared to 4.4% pre-intervention (p < .001). A one-point increase in OC improved the probability of becoming reporter by 2.9% and a one-point increase in skills by 6.4%.

Conclusion: MIs reporting competence among RNs increased after a multifaceted institutional intervention, due to an improvement in the skills dimension. The MII was also effective in raising both, the rate of RNs who become reporters and the number of no-harm MIs reported.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Patient Safety
  • Pharmacovigilance*
  • Spain
  • Surveys and Questionnaires